Soligenix, Inc.
(NASDAQ : SNGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 7.68%161.380.0%$1898.51m
OCGNOcugen, Inc. 6.32%8.750.0%$1079.84m
BNTXBioNTech SE 6.63%192.770.0%$872.52m
AMGNAmgen, Inc. 0.43%251.381.3%$740.91m
NVAXNovavax, Inc. 8.84%131.6979.8%$572.50m
SNSSSunesis Pharmaceuticals, Inc. 0.26%7.680.7%$536.86m
GILDGilead Sciences, Inc. -0.55%68.531.0%$504.56m
REGNRegeneron Pharmaceuticals, Inc. -0.11%516.622.7%$432.65m
ALXNAlexion Pharmaceuticals, Inc. 0.09%173.492.0%$412.31m
VRTXVertex Pharmaceuticals, Inc. 1.28%217.091.9%$311.54m
ILMNIllumina, Inc. 2.03%381.033.5%$302.74m
BIIBBiogen, Inc. -0.53%280.211.7%$269.43m
VXRTVaxart, Inc. 4.92%6.610.0%$240.79m
CRSPCRISPR Therapeutics AG 5.58%106.640.6%$171.41m
BNGOBionano Genomics, Inc. 22.45%5.400.0%$162.77m

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.